Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 7Neoplasm Metastasis 4Recurrence 3Non Small Cell Lung Cancer Metastatic 3Neuroblastoma 3Neoplasms 3Meningeal Carcinomatosis 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Thrombocytosis 1Sexual Dysfunction, Physiological 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × lorlatinib × Clear all
NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Pfizer

Phase 1 Terminated
1 enrolled 3 charts
Thoracic

Lung Neoplasms, Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡